Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Mechanisms and Medicines for Remyelination

Mechanisms and Medicines for Remyelination Demyelination of central nervous system axons, associated with traumatic injury and demyelinating diseases such as multiple sclerosis, causes impaired neural transmission and ultimately axon degeneration. Consequently, extensive research has focused on signaling systems that promote myelinating activity of oligodendrocytes or promote production of new oligodendrocytes from oligodendrocyte progenitor cells. Many receptor systems, notably including growth factor receptors and G protein–coupled receptors, control myelination. A number of recent clinical trials target these receptor signaling pathways. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annual Review of Medicine Annual Reviews

Mechanisms and Medicines for Remyelination

Annual Review of Medicine , Volume 68 – Jan 14, 2017

Loading next page...
 
/lp/annual-reviews/mechanisms-and-medicines-for-remyelination-T6oWhpzKlB
Publisher
Annual Reviews
Copyright
Copyright © 2017 by Annual Reviews. All rights reserved
ISSN
0066-4219
eISSN
1545-326X
DOI
10.1146/annurev-med-050715-104400
pmid
27860545
Publisher site
See Article on Publisher Site

Abstract

Demyelination of central nervous system axons, associated with traumatic injury and demyelinating diseases such as multiple sclerosis, causes impaired neural transmission and ultimately axon degeneration. Consequently, extensive research has focused on signaling systems that promote myelinating activity of oligodendrocytes or promote production of new oligodendrocytes from oligodendrocyte progenitor cells. Many receptor systems, notably including growth factor receptors and G protein–coupled receptors, control myelination. A number of recent clinical trials target these receptor signaling pathways.

Journal

Annual Review of MedicineAnnual Reviews

Published: Jan 14, 2017

There are no references for this article.